ABSTRACT
Background: Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need. Patients and methods: Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry. Results: A total of 175 patients were included. Median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0-1, and 86.7% were included with stage IV disease. Histology was non-squamous in 77.1%. Sixty-five received nivolumab in second line (37.1%). Thirty-eight patients had brain metastasis (22%), and 39 (22.3%) liver metastasis and 126 (72%) had more than one metastatic location. The ORR was 15.7% with median Progression free survival (PFS) 2.8 months and median OS 5.81 months. Stage III vs IV and time since the beginning of the previous line of treatment ≥ 6 vs < 6 months were associated with better response. PS 2, time since the previous line of treatment < 6 vs ≥ 6 months, and more than one metastatic location were independently associated with shorter OS in multivariable analysis (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month). Finally, time since the previous treatment < 6 vs ≥ 6 months and more than one metastatic location were independently associated with shorter PFS in multivariable analysis (4.3 vs 2.3 months and 4.7 vs 2.3 months). Conclusion: Poor PS, short period of time since the previous treatment, and more than one metastatic location were associated with poorer prognostic
No disponible
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Antibodies, Monoclonal, Humanized/pharmacokinetics , Carcinoma, Non-Small-Cell Lung/pathology , Lung Neoplasms/pathology , Retrospective Studies , Neoplasm Recurrence, Local/prevention & controlABSTRACT
Clinical and Translational Oncology.
ABSTRACT
BACKGROUND: Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need. PATIENTS AND METHODS: Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry. RESULTS: A total of 175 patients were included. Median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0-1, and 86.7% were included with stage IV disease. Histology was non-squamous in 77.1%. Sixty-five received nivolumab in second line (37.1%). Thirty-eight patients had brain metastasis (22%), and 39 (22.3%) liver metastasis and 126 (72%) had more than one metastatic location. The ORR was 15.7% with median Progression free survival (PFS) 2.8 months and median OS 5.81 months. Stage III vs IV and time since the beginning of the previous line of treatment ≥ 6 vs < 6 months were associated with better response. PS 2, time since the previous line of treatment < 6 vs ≥ 6 months, and more than one metastatic location were independently associated with shorter OS in multivariable analysis (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month). Finally, time since the previous treatment < 6 vs ≥ 6 months and more than one metastatic location were independently associated with shorter PFS in multivariable analysis (4.3 vs 2.3 months and 4.7 vs 2.3 months). CONCLUSION: Poor PS, short period of time since the previous treatment, and more than one metastatic location were associated with poorer prognostic.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Carcinoma, Non-Small-Cell Lung/secondary , Carcinoma, Squamous Cell/secondary , Lung Neoplasms/pathology , Neoplasm Recurrence, Local/pathology , Aged , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Squamous Cell/drug therapy , Female , Follow-Up Studies , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local/drug therapy , Nivolumab , Prognosis , Retrospective Studies , Survival RateABSTRACT
Rituximab is a treatment option to non-Hodg kin's diffuse large B-cell lymphoma (NHDLBCL) in advanced stage and comorbility. It is known the cardiotoxicity effect of this drug, but there is no previous report describing a complete atrioventricular block (CAVB) secundary to treatment with Rituximab. We present an elderly woman treated with monotherapy with Rituximab who experienced a CAVB after administration of the fifth dose of this drug.
Subject(s)
Antibodies, Monoclonal/adverse effects , Antineoplastic Agents/adverse effects , Atrioventricular Block/chemically induced , Lymphoma, Large B-Cell, Diffuse/drug therapy , Aged, 80 and over , Antibodies, Monoclonal, Murine-Derived , Dyslipidemias/complications , Female , Humans , Lymphoma, Large B-Cell, Diffuse/physiopathology , Rituximab , Spinal Osteophytosis/complications , Stroke/complications , Venous Thrombosis/complicationsABSTRACT
The main treatment of asctrocytomas is surgery, which serves a double purpose: diagnosis and treatment. Surgery can be complemented with radiotherapy. With respect to chemotherapy, there continues to be a controversy as to whether it has the capacity to overcome the blood-brain barrier. An interesting option has been the implantation of biodegradable polymers of carmustine that are placed in the cavity left by the surgical procedure. With respect to the cerebral edema that can be associated with the carmustine implants, there can appear images in follow-up that are suggestive of relapse.
Subject(s)
Astrocytoma/diagnosis , Brain Edema/diagnostic imaging , Brain Neoplasms/diagnosis , Neoplasm Recurrence, Local/diagnosis , Adult , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/adverse effects , Astrocytoma/therapy , Brain Edema/chemically induced , Brain Neoplasms/therapy , Carmustine/administration & dosage , Carmustine/adverse effects , Combined Modality Therapy , Decanoic Acids/administration & dosage , Decanoic Acids/adverse effects , Female , Humans , Magnetic Resonance Imaging , Neoplasm Recurrence, Local/drug therapy , Neurosurgical Procedures , Polyesters/administration & dosage , Polyesters/adverse effects , Positron-Emission Tomography , Radiography , RadiotherapyABSTRACT
The main treatment of asctrocytomas is surgery, which serves a double purpose: diagnosis and treatment. Surgery can be complemented with radiotherapy. With respect to chemotherapy, there continues to be a controversy as to whether it has the capacity to overcome the blood-brain barrier. An interesting option has been the implantation of biodegradable polymers of carmustine that are placed in the cavity left by the surgical procedure. With respect to the cerebral edema that can be associated with the carmustine implants, there can appear images in follow-up that are suggestive of relapse (AU)
Subject(s)
Humans , Female , Adult , Antineoplastic Agents, Alkylating/administration & dosage , Antineoplastic Agents, Alkylating/adverse effects , Astrocytoma/diagnosis , Astrocytoma/therapy , Brain Edema/chemically induced , Brain Edema , Brain Neoplasms/diagnosis , Brain Neoplasms/therapy , Carmustine/administration & dosage , Carmustine/adverse effects , Decanoic Acids/administration & dosage , Decanoic Acids/adverse effects , Magnetic Resonance Imaging , Neurosurgical Procedures , Polyesters/administration & dosage , Polyesters/adverse effects , Positron-Emission Tomography , RadiotherapyABSTRACT
The majority of deaths due to breast cancer occur in the context of complications secondary to metastatic disease. Trastuzumab, as a second line treatment, has shown a 15% objective response rate in patients with metastatic breast cancer. We present the case of a patient with two breast tumours, the second of more aggressive characteristics, with negative hormone receptors and c-erb-B2 +++, and with few therapeutic options due to her hepatic insufficiency secondary to metastatic disease; she was administered herceptin as monotherapy, and she had a complete clinical response. Trastuzumab has revolutionised the management of patients with metastatic breast cancer and Her-2- neu overexpression. Its combination with chemotherapy agents achieves a synergic activity (AU)
Subject(s)
Humans , Female , Aged , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/therapeutic use , Antineoplastic Agents, Hormonal/administration & dosage , Antineoplastic Agents, Hormonal/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/drug therapy , Bone Neoplasms/secondary , Breast/pathology , Biopsy , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Cisplatin/therapeutic use , Tamoxifen/administration & dosage , Tamoxifen/therapeutic use , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/radiotherapy , Carcinoma, Ductal, Breast/secondary , Carcinoma, Ductal, Breast/surgery , Time FactorsSubject(s)
Antineoplastic Agents/adverse effects , Drug Eruptions/etiology , Exanthema/chemically induced , Gallbladder Diseases/chemically induced , Hand Dermatoses/chemically induced , Hodgkin Disease/drug therapy , Adult , Bleomycin/adverse effects , Dacarbazine/adverse effects , Doxorubicin/adverse effects , Humans , Male , Vinblastine/adverse effectsABSTRACT
Metastasis to the thyroid occur infrequently. The overall incidence in autopsy series vary from 0-5% in unselected cases to 24% in patients with a known malignancy. They usually occur when there are another metastases, sometimes many years after diagnosis of the original primary tumour. We present the case of a woman with dysphagia and dysphonia due to a thyroid mass as first manifestation of a metastatic breast cancer.
Subject(s)
Breast Neoplasms/pathology , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/secondary , Deglutition Disorders/etiology , Female , Humans , Middle Aged , Voice Disorders/etiologyABSTRACT
Clinical benefits of hormone therapy in patients with hormone-sensitive tumors have been clearly established. Postmenopausal women with positive hormone receptors represent the largest group of patients in whom early stage breast cancer is diagnosed. Third-generation aromatase inhibitors (letrozole, anastrozole, and exemestane) are active and well tolerated in postmenopausal women with hormone-sensitive metastasic or locally advanced breast cancer as first or second line treatment. These are also valuable agents in the neoadjuvant setting in postmenopausal women, and even as single treatment in localized breast tumors in women not amenable to surgery.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Aromatase Inhibitors/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Estrogens , Neoplasm Proteins/analysis , Neoplasms, Hormone-Dependent/drug therapy , Nitriles/therapeutic use , Receptors, Estrogen/analysis , Triazoles/therapeutic use , Aged , Aged, 80 and over , Anastrozole , Breast Neoplasms/chemistry , Breast Neoplasms/diagnostic imaging , Carcinoma, Ductal, Breast/chemistry , Carcinoma, Ductal, Breast/diagnostic imaging , Contraindications , Female , Humans , Letrozole , Mastectomy , Neoadjuvant Therapy , Postmenopause , RadiographySubject(s)
Anemia, Hemolytic/chemically induced , Deoxycytidine/analogs & derivatives , Gilbert Disease/complications , Adult , Anemia, Hemolytic/etiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/complications , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgery , Capecitabine , Chemotherapy, Adjuvant , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Epirubicin/administration & dosage , Female , Fluorouracil/analogs & derivatives , Humans , Hyperbilirubinemia/etiology , Mastectomy, Segmental , Radiotherapy, Adjuvant , Randomized Controlled Trials as TopicABSTRACT
No disponible
No disponible
Subject(s)
Male , Adult , Humans , Hodgkin Disease/complications , Hodgkin Disease/diagnosis , Exanthema/complications , Exanthema/diagnosis , Lymphoma/complications , Dermatitis/complications , Dermatitis/diagnosis , Dermatitis/drug therapy , Mupirocin/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Tomography, Emission-Computed/methods , Bleomycin/adverse effects , Vinblastine/adverse effects , Dacarbazine/adverse effectsABSTRACT
No disponible
Subject(s)
Female , Adult , Humans , Anemia, Hemolytic/chemically induced , Deoxycytidine/analogs & derivatives , Gilbert Disease/complications , Anemia, Hemolytic/etiology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemotherapy, Adjuvant , Cyclophosphamide/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Epirubicin/administration & dosage , Hyperbilirubinemia/etiology , Mastectomy, Segmental , Breast Neoplasms/complications , Breast Neoplasms/drug therapy , Breast Neoplasms/radiotherapy , Breast Neoplasms/surgeryABSTRACT
No disponible
Subject(s)
Male , Middle Aged , Humans , Carcinoma, Squamous Cell/complications , Tracheoesophageal Fistula/etiology , Tracheoesophageal Fistula/surgery , Stents , Gastrointestinal Neoplasms/complicationsABSTRACT
Tuberculosis and cancer are two processes in relationship. The relation between both are studied. We analyzed retrospectively the culture-positive tuberculosis cases in from 1999 to 2002. We described the six cases with tuberculosis and cancer. One hundred and five cases of tuberculosis were observed, 6 cases (5.7%) had cancer. Four cases were pulmonary tuberculosis, one tuberculous pleurisy and other urinary tuberculosis urinary. The two cases with bronchogenic neoplasm had a diagnosis of tuberculosis at same time than cancer. The diagnosis of neoplasm was previous than tuberculosis in two cases (breast neoplasm and hypernephroma), and posterior in others two cases (breast and colon neoplasm). Half of theses patients died. In patients with neoplasm, the possibility of coexist tuberculosis is not depreciable, previous, concomitant or after the diagnosis of neoplasm.
Subject(s)
Neoplasms/complications , Tuberculosis/complications , Adult , Aged , Female , Hospitals, General , Humans , Male , Middle Aged , Retrospective Studies , SpainABSTRACT
Tuberculosis y cáncer son dos procesos que pueden aparecer interrelacionados. Se estudia la asociación entre ambas entidades. Se han revisado de forma retrospectiva los casos diagnosticados microbiológicamente de tuberculosis en el Hospital General Universitario de Elche desde 1999 a 2002. En seis pacientes coexistía neoplasia y tuberculosis. Se diagnosticaron 105 casos de tuberculosis, 6 de los cuales (5,7 por ciento) tenían una neoplasia. Cuatro tuvieron tuberculosis pulmonar, uno pleuropulmonar y otro urinaria. Los dos pacientes con carcinoma broncogénico tuvieron un diagnóstico sincrónico de tuberculosis pulmonar. El diagnóstico de la neoplasia previo al de tuberculosis fue en dos casos (cáncer de mama e hipernefroma), y posterior en otros dos (cáncer de mama y de colon). La mitad de los pacientes fallecieron. En los pacientes con neoplasia la posibilidad de coexistencia de tuberculosis no es despreciable, tanto previo al diagnóstico, concomitantemente, o tras el mismo (AU)
